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The porphyrias are disorders of porphyrin metabolism
that result from inherited or acquired aberrations in the
control of the heme biosynthetic pathway. Variegate
porphyria is characterized by a partial reduction in the
activity of protoporphyrinogen oxidase. In this study, we
identified the first nonsense mutation in a family with
variegate porphyria. The mutation consisted of a previ-
ously unreported G-to-T transversion in exon 5 of the
The porphyrias are disorders of heme metabolism resultingfrom the inherited or acquired dysregulation of one ofthe eight enzymes that control the porphyrin-hemebiosynthetic pathway. Variegate porphyria (VP), oneof the acute hepatic porphyrias, is characterized by
deficiencies in protoporphyrinogen oxidase (PPO), the seventh enzyme
in the pathway of heme biosynthesis (Frank and Christiano, 1997).
Biochemically, increased levels of porphyrin precursors, raised values
of protoporphyrin, coproporphyrin, and pentacarboxyporphyrin in the
feces, and, possibly, increased porphyrins in the urine and plasma can
be found (Day, 1986). VP is usually inherited as an autosomal dominant
trait displaying incomplete penetrance, as not all persons carrying a
mutation in the PPO gene develop the clinical phenotype (Frank and
Christiano, 1997). In heterozygotes, PPO activity is decreased by
µ50% (Eales et al, 1980).
The cutaneous manifestations of VP include increased photo-
sensitivity, blistering, skin fragility with chronic scarring of sun-exposed
areas, and postinflammatory hyperpigmentation (Bickers et al, 1993).
The photosensitivity may occur alone or in combination with acute
symptoms such as abdominal pain, the passage of dark urine, and
neuropsychiatric crises, which characterize the acute hepatic porphyrias.
In heterozygotes, the disease does not usually present before puberty
(Kauppinen and Mustajoki, 1992).
The human PPO cDNA and gene were recently cloned and mapped
to chromosome 1q22–23 (Nishimura et al, 1995; Roberts et al, 1995;
Taketani et al, 1995a), and we and others have recently identified
pathogenic mutations in several families with VP (Deybach et al, 1996;
Meissner et al, 1996; Warnich et al, 1996; Frank and Christiano, 1997;
Lam et al, 1997).
In this study, we investigated a proband with VP and three of her
clinically unaffected family members. We identified a nonsense mutation
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protoporphyrinogen oxidase gene, resulting in the substi-
tution of glutamic acid by a nonsense codon, designated
E133X. Our investigation establishes that a nonsense
mutation in the protoporphyrinogen oxidase gene is
the underlying mutation in this family with variegate
porphyria. Key words: bullous diseases/genodermatosis/photo-
sensitivity/porphyrin-heme biosynthetic pathway. J Invest
Dermatol 110:449–451, 1998
in the PPO gene in the clinically affected patient and one of her sons
by heteroduplex analysis, automated sequencing, and allele specific
oligonucleotide (ASO) hybridization. The mutation consisted of a
previously unreported G-to-T transversion in exon 5 of the PPO
gene, resulting in the substitution of glutamic acid by a premature
termination codon. Our study establishes this nonsense mutation as
the underlying defect in the PPO gene in this patient with VP.
MATERIALS AND METHODS
Clinical material and biochemical analyses We investigated the proband,
three of her family members, and 50 unrelated, unaffected control individuals.
The proband is a 35 y old female of German ancestry who was diagnosed with
VP clinically and by biochemical porphyrin analysis (Table I) in 1992. Her
mother and her two sons were clinically unaffected with VP. Blood samples
from the family were collected in tubes containing ethylenediamine tetraacetic
acid. All individuals provided informed consent for inclusion in the study, in
accordance with guidelines set forth by the local institutional review board.
Genomic DNA was isolated according to standard techniques (Sambrook
et al, 1989).
PCR amplification and mutation detection A mutation detection strategy
was developed for PCR amplification of all PPO exons using PCR primers
that were published recently (Warnich et al, 1996). For amplification of exon
5 of the PPO gene in this specific case, the following primers were used, as
described recently (Warnich et al, 1996): PPO Exon 5L, 59 GAGGTATGT-
CAGGAGCTTCC 39; and PPO Exon 5R, 59 GATTTGAACAGGGAGCT-
CTG 39.
PCR was carried out on genomic DNA from all family members according
to the following program: 95°C for 10 min; followed by 40 cycles of 95°C for
45 s, 57°C for 45 s, and 72°C for 1 min; followed by 72°C for 15 min, in an
OmniGene thermal cycler (Marsh Scientific, Rochester, NY). For mutation
detection, PCR products were subjected to conformation sensitive gel electro-
phoresis (CSGE) analysis as described previously (Ganguly et al, 1993). PCR
products displaying a heteroduplex on CSGE analysis were sequenced using an
ABI Prism 310 Genetic Analyzer from Applied Biosystems.
For confirmation of the G-to-T transversion in exon 5 at the genomic DNA
level, ASO hybridization was carried out in an independently generated PCR
product according to standard techniques (Sambrook et al, 1989). In this
case, the following oligonucleotides were used: Oligo exon 5 wild-type, 59
GGGCTGAGGGAGCTGACC 39; Oligo exon 5 mutant, 59
GGCTGAGGTAGCTGACCA 39.
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Figure 1. Mutation analysis in the VP patient in this study and her
family members. (A) Pedigree of the nuclear family with regard to the
occurrence of VP; the proband (II/1) is indicated by a half-filled circle. The
other family member carrying the E133X mutation (III/1) is indicated by a
half-filled square. (B) Heteroduplex analysis of the family and a control (C);
heteroduplex formation in the proband (II/1) and one of her sons (III/1) in
exon 5 of the PPO gene. (C) ASO hybridization results: in exon 5, the proband
(II/1) and her son (III/1) show the mutant E133X allele (lower panel) and the
wild-type allele, whereas the other family members (I/1 and III/2) and the
control (C) only show the wild-type allele (upper panel). (D) Automated
sequence of the forward strand of the PCR fragment of exon 5; G-to-T
transversion in exon 5 of the proband (lower panel, indicated by an arrow)
compared with the wild-type sequence of control C (upper panel).
Table I. Diagnostic porphyrin analysis of the proband
Porphyrin analysis Proband Reference ranges
Urine
Total urinary porphyrins 848 µg/l ,150 µg/l
Urinary ALA 12.2 mg/l ,5.0 mg/l
Urinary porphobilinogen 9.9 mg/l ,9.9 mg/l
Stool
Total fecal porphyrins 1084 nmol/g ,200 nmol/g
RESULTS
Heteroduplex analysis of exon 5 of the PPO gene in this family
(Fig 1A), revealed a heteroduplex in the proband and one son (Fig 1B).
Automated sequence analysis of this PCR product in all family members
revealed the same sequence variant in the patient and her son (Fig 1D).
The mutation consisted of a G-to-T transversion at nucleotide position
396 of the PPO cDNA (numbered according to GenBank #D38537,
counting the first base of the initiating methionine as #1), leading to
a previously unreported nonsense mutation consisting of an amino acid
conversion from glutamic acid to a nonsense codon at position 133
(E133X) in the deduced amino acid sequence (Fig 2). Heteroduplex
analysis of exon 5 of the PPO gene was also performed in 50 unrelated
control individuals and showed no heteroduplex formation indicative
of the mutation (data not shown). Because the mutation did not
introduce a restriction site for any known restriction endonuclease,
ASO hybridization was carried out to verify the sequence variation.
In the proband and one son, the normal as well as the mutant
allele was observed, indicating that they are heterozygous for the
mutation (Fig 1C).
Figure 2. Alignment of deduced amino acid sequences from codons
131 to 140 in exon 5 of human PPO (hPPO), mouse PPO (mPPO),
and the yeast Saccharomyces cerevisiae (SC hem 14). The identical residues
in codon 133 and the substitution derived from the described nonsense mutation
are shaded and bold.
Table II. Reported mutations in the PPO gene
Location Designation Consequence Reference
Dominant VP
exon 3 165insAG Frameshift mutation Lam et al, 1997
exon 7 1022insG Frameshift mutation Deybach et al, 1996
exon 10 1083deIT Frameshift mutation Frank and Christiano,
1997
exon 11 1144delGT Frameshift mutation Frank and Christiano,
1997
exon 2 H20P Missense mutation Warnich et al, 1996
exon 3 R59W Missense mutation Warnich et al, 1996
Meissner et al, 1996
exon 6 R168C Missense mutation Warnich et al, 1996
Meissner et al, 1996
exon 7 G232R Missense mutation Deybach et al, 1996
exon 13 S450P Missense mutation Frank and Christiano,
1997
exon 5 E133X Nonsense mutation This study
Recessive VP
exon 6/10 G169E/G358R Compound Frank et al, 1998
heterozygote
missense mutation
DISCUSSION
We report the identification of a nonsense mutation in a patient with
VP and her unaffected son by CSGE analysis, automated sequencing,
and ASO hybridization. To date, 12 different mutations have been
detected in the PPO gene on chromosome 1q22–23 (Table II),
demonstrating the heterogeneity of VP (Deybach et al, 1996; Meissner
et al, 1996; Warnich et al, 1996; Frank and Christiano, 1997; Lam et al,
1997). These mutations reflect a wide spectrum of possible types of
mutations, including single base substitutions (transitions and transver-
sions) as well as deletions and insertions in the PPO gene.
The mutation found in this study consisted of a previously unreported
G-to-T transversion in exon 5 of the PPO gene, leading to the
substitution of a glutamic acid residue by a nonsense codon (E133X).
This mutation was the only sequence variant detected in this family.
Interestingly, a comparison of nucleotide deduced amino acid sequences
(Fig 2) revealed that this conversion occurred in a region of PPO that
is strictly conserved in human (Nishimura et al, 1995), in mouse over
90 million evolutionary years (Taketani et al, 1995a), and over 500
million evolutionary years in the yeast Saccharomyces cerevisiae (Camadro
et al, 1996), although their entire amino acid sequence identity is less
than 20%. Therefore, this glutamic acid residue is believed to be highly
important for proper functioning of PPO. The mutation may cause
disturbances of specific regions in PPO and thereby impair the integrity
of the protein. Although we did not measure mRNA levels in this
study, there is evidence that nonsense mutations are associated with
dramatically reduced amounts of cytoplasmic mRNA, which presum-
ably leads to the elimination of the production of protein that is
potentially deleterious to cell viability (Cooper, 1993; Maquat, 1996).
Previous studies have shown that VP displays a high variability in the
clinical expression of defects in the PPO gene within family members
carrying the same mutation (Deybach et al, 1996), suggesting the
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influence of genetic background on the expression of the disease
phenotype. The reasons for the different patterns of inheritance and
differences in phenotypic severity in VP are not well understood, and
require further investigation.
Once a mutation has been identified in a VP patient, the detection
of asymptomatic carriers within the patient’s family is easily accomp-
lished using molecular biologic techniques. The identification of these
so-called ‘‘silent carriers’’ is the first and most important step in the
prevention of acute attacks.
This study underscores the phenotypic variability in VP in a family
with carriers of the same nonsense mutation in the PPO gene. There
is little doubt that DNA analysis will be the method of choice to
confirm putative diagnosis of VP, and consequently, to prevent acute
attacks in ‘‘silent’’ carriers of mutations. Further investigations are
underway to establish genotype-to-phenotype correlations in VP by
the expression of mutant alleles, and to understand additional and
unusual mechanisms of inheritance in this disease.
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